Here are the key details to know:
1. David J. Mazzo, PhD, is stepping down as non-executive chairman and will remain on the board to serve as the chair of the compensation committee.
2. Dr. Ando was appointed to the EyePoint board of directors in June 2018. He previously served as Novo Nordisk’s chairman of the board. He currently serves as a EW Healthcare Partners’ senior advisor.
3. Dr. Ando began his career at Pfizer where he held several senior clinical positions in the U.S. and Europe.
More articles on supply chain:
Baxter’s bone graft substitute approved for orthopedic procedures — 5 facts
3 Ways to cut operating room inventory in an ASC
ASC supply chain tip of the day: Reduce waste
